Selective removal of toxic cholesterol restores immune function in foam cells, paving the way for human trials of novel compound UDP-003.
The central role of 7-ketocholesterol (7KC) in the pathogenesis of atherosclerosis is well documented: as a toxic oxidized derivative of cholesterol, 7KC accumulates in arterial walls and contributes to the transformation of macrophages into dysfunctional, lipid-laden foam cells. These cells drive inflammation, destabilise plaque and ultimately fuel cardiovascular disease – the leading cause of mortality worldwide.
Many therapeutic strategies have focused on lipid lowering or anti-inflammatory approaches; few have attempted to directly remove 7KC from cells, and fewer still have demonstrated the ability to reverse foam cell formation. Now, Cyclarity Therapeutics has published preclinical data suggesting its cyclodextrin-based compound UDP-003 can do just that – and with a favorable safety and pharmacokinetic profile that supports IND-readiness for first-in-human trials [1].
The study, led by Bhargava et al and published in Atherosclerosis, used a combination of in vitro and ex vivo models to show that UDP-003 not only prevents the formation of foam cells, but restores macrophage function even after 7KC-induced damage has occurred. Treatment reduced intracellular lipid accumulation, oxidative stress and inflammatory gene expression, while improving cholesterol efflux, phagocytosis and efferocytosis – critical functions that are typically impaired in advanced atherosclerosis.
Longevity.Technology: We’ve previously described Cyclarity’s UDP‑003 as a potentially first-in-class disease-modifying therapy for atherosclerosis – and this new data reinforces that narrative; foam cells, long considered the irredeemable culprits of arterial plaque, are here not merely halted in their decline, but restored to functioning macrophages with renewed phagocytic and efferocytic vigor. This is not symptomatic management, nor is it another play at lipid tinkering; it is mechanistic repair at the cellular level – long theorised, often promised, rarely delivered. UDP‑003 is a textbook Level 7 therapeutic – targeting a specific age-related pathology and restoring lost cellular function with translational precision. Cyclarity’s approach walks the line between elegant chemistry and pragmatic translational science – dimerized cyclodextrins may not sound glamorous, but their high selectivity for 7KC and their performance in human plaque tissue lend serious weight to a platform that, unusually for this sector, is both IND-ready and mechanistically transparent.
The company continues to present itself less as a disruptor and more as an engineer – precise, deliberate and quietly confident – and if upcoming clinical trials bear out these early findings, UDP‑003 could be the molecule that finally bridges the stubborn translational gap between lab bench rejuvenation and meaningful, measurable patient outcomes.
From selectivity to system-wide promise
Cyclodextrins, the core chemical structure of UDP-003, are cyclic sugar-based molecules capable of encapsulating lipophilic compounds such as cholesterol. While some forms of cyclodextrins have been used as excipients or in experimental cholesterol efflux therapies, the dimeric structure of UDP-003 confers around 1,000-fold greater selectivity for 7KC over cholesterol, according to the authors [1].
This selectivity appears to be central to the compound’s ability to remove 7KC from human atherosclerotic plaque tissue in as little as 15 minutes, and to promote urinary excretion of the toxin in vivo. Notably, these effects occurred without significant toxicity; UDP-003 has completed a suite of preclinical safety studies and is now considered ready for clinical development.
Writing in a commentary, Professor Gérard Lizard – a leading expert in oxysterols and their role in age-related disease – described the data as “very attractive and of great interest,” suggesting that the ability to remove 7KC “constitutes the innovative curative aspect of this molecule” [2].
Beyond cardiovascular disease
Although the current focus is on atherosclerosis, 7KC is increasingly recognised as a broader marker of age-related pathology. Elevated levels have been found in conditions ranging from macular degeneration to Alzheimer’s disease, and the mechanisms of toxicity – mitochondrial dysfunction, oxidative stress and impaired cellular clearance – overlap substantially with hallmarks of aging.
UDP-003’s potential, therefore, may extend beyond the vascular system. As the commentary notes, its mechanism could make it a candidate for treating other diseases of aging where 7KC plays a role – though clinical data will, of course, be required to support any such expansion.
Patience in the pipeline
There is, as ever, a need for caution. While the restoration of macrophage function is notable, plaque regression was not clearly demonstrated in animal models. Efficacy in lesion reduction is still unproven in vivo – likely reflecting limitations of murine physiology rather than a lack of therapeutic effect. The pharmacokinetics of the drug, including its rapid urinary excretion, will also need to be carefully managed in trial design to ensure sustained tissue exposure.
Nevertheless, the selective removal of a toxic molecule long implicated in cellular aging and cardiovascular disease is a welcome intervention – both for its scientific rationale and for its potential to shift the therapeutic goalposts
The real test comes next
Whether UDP-003 becomes the first disease-modifying therapy for atherosclerosis will depend not just on continued molecular precision, but on clinical performance. However, the clarity of its mechanism and the rigor of its preclinical profile suggest that Cyclarity’s progress is worth watching – and, most likely, worth waiting for.
[1] https://www.atherosclerosis-journal.com/article/S0021-9150(25)00115-7/
[2] https://doi.org/10.1016/j.atherosclerosis.2025.120419
